NEKTAR THERAPEUTICS
About NEKTAR THERAPEUTICS
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $55.2M
- Net income
- -$164.1M
- Total assets
- $280.4M
- Market cap
- $1.9B
- Operating margin
- -253.7%
- Net margin
- -297.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $55.2M
- Cost of revenue
- $0
- Operating expenses
- $195.3M
- Operating income
- -$140.1M
- Income tax
- -$138.0K
- Net income
- -$164.1M
- EPS (basic)
- $-9.73
- EPS (diluted)
- $-9.73
Balance sheet
- Total assets
- $280.4M
- Current assets
- $266.3M
- Total liabilities
- $190.6M
- Current liabilities
- $53.5M
- Shareholders’ equity
- $89.8M
Cash flow
- Operating cash flow
- -$208.5M
- Investing cash flow
- -$1.2M
- Financing cash flow
- $180.6M
- Net cash flow
- -$29.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-9.73
- Shares outstanding
- 34.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 3, 1994
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $164.1M in FY2025.
- Revenue declined 46% from FY2021 to FY2025.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NEKTAR THERAPEUTICS.
Write a review
News about NEKTAR THERAPEUTICS
News & sentiment via Polygon.io
